We announce our new strategy, how our scientists plot ‘extinction’ of cancers by disrupting their ecosystems, a new drug combination shows promise against cancer’s ‘death star’ protein, and a new immunotherapy shows early promise in range of solid tumours.
Treatment combinations show promise in various different cancers, Covid jab provides protection for most myeloma blood cancer patients and the ICR announces appointment of new Chief Executive.
Cancer vaccine could boost the effectiveness of immunotherapy, most innovative cancer drugs facing delays in reaching patients, and cancers engaged in evolutionary arms race with immune system.
Triple drug combinations could prevent resistance in many cancer types, new ‘Trojan horse’ cancer treatment and new AI ‘shapeshift’ test identifies women with ‘very high risk’ ovarian cancer.
Likely cause of childhood leukaemia revealed, Queen's Anniversary Prize, and scientists find treasure trove of 110 genes linked to breast cancer.
Immune system genes linked to leukaemia, largest ever brain cancer study, ASCO 2017 conference, and new genetic cause of kidney cancer in children identified.
The London Cancer Hub announced, new research strategy, BBC 'Shine a light on cancer', MR Linac launch with Mayor of London
BBC Panorama appearance, manipulating cell shape and a new role for an 'old' cancer gene.
Launching The Centre for Evolution and Cancer, the ICR brought experts in the methods and theories of Evolutionary Biology into their multidisciplinary cancer research team.
The ICR began a a new push to bring personalised treatments to patients, with its Tumour Profiling Unit.
ICR-developed drug abiraterone was recommended for prostate cancer patients on the NHS, and the ICR opened the Centre for Molecular Pathology.
Europe's leading cancer research centre, The Institute of Cancer Research (ICR), named eminent scientist Professor Alan Ashworth as its new Chief Executive.
Phase III trial results showed that the drug abiraterone, developed at the ICR, can significantly extend overall survival for men with advanced prostate cancer.
2009 marked the centenary year for the ICR, which began life as a small research laboratory in the Royal Marsden Hospital.
The ICR announced that the drug abiraterone could treat up to 80% of patients with aggressive and previously drug resistant prostate cancer.
ICR scientists identified two common genetic variants that could triple a person’s risk of getting bowel cancer.
The complex chain of molecular triggers involved in the development of malignant melanoma, the deadliest form of skin cancer, was published by the ICR.